UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

Both my parents use CPAP machines to treat their sleep apnea so ... but there are also bundles for ResMed AirSense 10 ($339), Fisher & Paykel ICON ($339), and others. The white sanitizing chamber ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep.

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...